CRANBURY, N.J., July 25, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the publication of a paper in The Journal of Molecular Medicine (http://tinyurl.com/3ugohzd) describing the selective inhibition of cancer cell energy metabolism by its novel lipoate derivative compounds. Specifically, the publication illuminates the mechanism by which CPI-613, a lipoic acid analog, selectively attacks the regulatory aspects of tumor cell mitochondrial metabolism, activating both apoptotic (programmed cell death) and non-apoptotic (necrosis-like) cell death pathways. This research was conducted in collaboration between scientists at Stony Brook University and Cornerstone Pharmaceuticals. The paper "Non-redox-active lipoate derivatives disrupt cancer cell mitochondrial metabolism and are potent anti-cancer agents in vivo" is available today in the advanced online publication of The Journal of Molecular Medicine. The full author's version of the paper is available here: http://tinyurl.com/3gvx5oa
"The highly reconfigured metabolism of cancer cells has recently gained wide attention as a possible source of novel drug targets," said Dr. Zuzana Zachar, Ph.D., the lead author of the paper who is Director of Research at Cornerstone and a Research Assistant Professor at Stony Brook University School of Medicine.
"CPI-613 attacks cancer cell metabolism in a powerful new way, yielding very strong anti-cancer effects in pre-clinical human tumor models," added Dr. Paul Bingham, Ph.D., co-author, and Vice President of Research at Cornerstone and Associate Professor at Stony Brook University School of Medicine.
CPI-613 is the lead drug candidate from Cornerstone's Altered Energy Metabol
|SOURCE Cornerstone Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved